SNES - SenesTech to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30 2024

PR Newswire

PHOENIX , May 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) today announced that Joel Fruendt , Chief Executive Officer, and Tom Chesterman , Chief Financial Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024 .

Company Webcast

The webcasted presentation will take place at 11:45am ET on Thursday, May 30, 2024 . The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2024/ or directly at https://wsw.com/webcast/lytham11/snes/2110185 .  The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/ .

About SenesTech

We are committed to improving the health of the world by humanely managing animal pest populations through our expertise in fertility control. We invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, as well as Evolve and Evolve Mouse, EPA-designated minimum risk contraceptives for rodents, reflecting our mission to provide products that are proactive, safe and sustainable. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. We strive for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable.

For more information visit https://senestech.com/ .

Safe Harbor Statement
Forward-looking statements include statements concerning results of operations and financial performance; the Company's strategy and target marketing and markets; continuing the Company's vision; expected benefits of the Company's initiatives and continuation of those initiatives; deployment of the Company's product; the continuation or expansion of the use of ContraPest; demand for ContraPest; the Company's expectation regarding costs, expenses and cash and continuing its cost improvement plan; future financial results; and the Company's execution of its strategic business plan.

CONTACT:

Investor: Robert Blum , Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com

Company: Tom Chesterman , Chief Financial Officer, SenesTech, Inc., 928-779-4143

SOURCE SenesTech, Inc.